Net Clinical Benefit of Rivaroxaban Compared With Wa
Results From ROCKET AF

International Journal of Cardiology

257, 78-83

DOI: 10.1016/j.ijcard.2017.06.110

Citation Report

#	Article	IF	Citations
1	Benefits and Risks of Extended Treatment of Venous Thromboembolism With Rivaroxaban or With Aspirin. Thrombosis Research, 2018, 168, 121-129.	2.9	10
2	Drug Persistence and Outcomes in a Cohort of Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban After 2 Years of Follow-Up in Clinical Practice. Future Cardiology, 2018, 14, 9-16.	1.2	6
3	Personalized Benefit-Risk Assessments Combining Clinical Trial and Real-World Data Provide Further Insights Into Which Patients May Benefit Most From Therapy: Demonstration for a New Oral Antiplatelet Therapy. Pharmacoepidemiology and Drug Safety, 2019, 28, 443-451.	2.6	7
4	Anticoagulación del paciente anciano pluripatológico con fibrilación auricular no valvular: papel del rivaroxabán. Revista Espanola De Cardiologia Suplementos, 2020, 20, 3-10.	0.2	0
5	Fibrilación auricular y cardiopatía isquémica: más allá de la prevención del ictus. Revista Espanola De Cardiologia Suplementos, 2020, 20, 11-20.	0.2	0
6	A Structured Literature Review and International Consensus Validation of FORTA Labels of Oral Anticoagulants for Long-Term Treatment of Atrial Fibrillation in Older Patients (OAC-FORTA 2019). Drugs and Aging, 2020, 37, 539-548.	4.9	10
7	Left Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation. Annals of Internal Medicine, 2022, 175, 1230-1239.	12.9	13
8	Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness. Journal of the American Heart Association, 2022, 11, e026229.	5.8	10
9	Non-Embolic Outcomes in Patients With Cardiovascular Disease and Atrial Fibrillation Treated With Rivaroxaban. Journal of Comparative Effectiveness Research, 2023, 12, e220049.	2.7	2
10	The Importance of Assessing the Safe and Effective Use of Oral Anticoagulants in Older Adults. Journal of the American Geriatrics Society, 2023, 71, 3954-3956.	3.9	2
11	Quantitative Benefit–Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association, 2024, 13, e032782.	5.8	11
12	Rivaroxaban Versus Apixaban: A Comparison Without a Simple Solution. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2024, 8, 321-328.	5.4	3
13	Benefit–Risk Assessment of Rivaroxaban in Older Patients With Nonvalvular Atrial Fibrillation or Venous Thromboembolism. Drugs and Aging, 2025, 42, 469-484.	4.9	3
14	Effects of Direct Oral Anticoagulants on Cardiac Outcomes in Atrial Fibrillation: A Systematic Review and Network Meta-Analysis. Internal and Emergency Medicine, 2026, 21, 2305-2320.	4.8	1